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Systemic-opportunistic fungal infections caused by triazole-resistant fungi, including 
Aspergillus fumigatus, are an emergent cause of human disease worldwide, as Aspergillus 
spp. are one of the most prevalent fungi in occupational environments. The antifungal drugs 
resistance makes it imperative to assess new compounds with antimicrobial and/or synergistic 
properties, to be utilized as adjuvants in combination antifungal therapy. Epigallocatechin-3-
gallate (EGCG), the main green tea constituent, has demonstrated anti-infective properties in 
several studies. The aim was to assess the antifungal potential of EGCG against triazole-
resistant Aspergillus fumigatus isolates collected in different occupational settings, and the 
potential synergistic effects between ECGC and commonly used antifungal drugs – 
itraconazole (ITR), voriconazole (VOR) and posaconazole (POS). Triazole-resistant 
Aspergillus fumigatus isolates (N=3) were grown in Sabouraud dextrose 4% agar. Inoculum 
suspensions (OD=0.060) were prepared with EGCG at final concentrations of 250µg/mL, 
100µg/mL, 50µg/mL, 25µg/mL and with no EGCG. Each suspension was spread onto RPMI-
1640 medium and Sabouraud dextrose 4% agar supplemented with 4μg/mL ITR, 2μg/mL 
VOR, 0.5μg/mL POS or with no supplementation, and incubated at 34-37ºC for 7 days 
(adapted from the EUCAST E.Def 10.1 method). One isolate grew on RPMI-1640 
supplemented with 2μg/mL VOR alone and with 25 and 50 μg/mL of EGCG, with no visible 
growth with EGCG concentrations above 100μg/mL, implying chemosensitization of the 
isolate. These results suggest that EGCG may be used as a possible adjuvant for combination 
antifungal therapy against triazole-resistant Aspergillus fumigatus. However further studies 





















Vários fungos resistentes aos triazóis, incluindo Aspergillus fumigatus são uma causa 
emergente de infeções sistémicas oportunistas, já que os Aspergillus spp. são dos fungos 
mais prevalentes em ambientes ocupacionais. O aumento da resistência aos antifúngicos 
torna imprescindível a avaliação de novos compostos com propriedades antifúngicas e/ou 
sinérgicas, para serem utilizados como adjuvantes na terapia fúngica combinada. A 
epigalocatequina-3-galato (EGCG), o principal constituinte do chá verde, demonstrou 
propriedades anti-infeciosas em vários estudos. Objetivou-se avaliar o potencial antifúngico 
da EGCG contra isolados de Aspergillus fumigatus resistentes a triazóis, colhidos em 
diferentes ambientes ocupacionais, e os potenciais efeitos sinérgicos entre a EGCG e os 
antifúngicos comumente usados – itraconazole (ITR), voriconazole (VOR) e posaconazole 
(POS). Os isolados de Aspergillus fumigatus resistentes a triazóis (N=3) foram cultivados em 
Sabouraud e preparadas suspensões fúngicas (OD=0.060) com EGCG em concentrações 
finais de 250µg/mL, 100µg/mL, 50µg/mL, 25µg/mL e sem EGCG. Cada suspensão foi 
inoculada em RPMI-1640 e Sabouraud suplementados com 4μg/mL ITR, 2μg/mL VOR, 
0.5μg/mL POS ou sem antifúngico e incubada a 34-37ºC durante 7 dias (adaptado do método 
EUCAST E.Def 10.1). Um isolado cresceu em RPMI-1640 suplementado apenas com 2μg/mL 
VOR e na presença de 25 e 50 μg/mL de EGCG, mas não apresentou crescimento em 
concentrações de EGCG superiores a 100μg/mL, indicando sensibilização do isolado. Estes 
resultados sugerem que a EGCG poderá ser usada como potencial adjuvante na terapia 
antifúngica combinada contra Aspergillus fumigatus resistentes a triazóis. Não obstante, mais 
estudos com amostras maiores devem ser realizados antes da translação destes resultados 
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Antifungal resistance is a growing threat. It develops when antifungal drugs are 
used properly for long periods of azole treatment and prophylaxis or improperly to treat 
sick people in clinical settings (e.g., when dosages are too low, or when treatment 
courses are not long enough), and may even arise from the exposure of fungi to 
fungicides in agricultural practice (1,2). Systemic, opportunistic and invasive fungal 
infections (IFI’s) caused by azole-resistant fungi, including Aspergillus fumigatus, are 
emerging as an important cause of human disease with associated high morbidity and 
mortality rates worldwide. Infections primarily occur in immunocompromised patients, 
such as those undergoing chemotherapy in health facilities. However, infections of 
otherwise healthy people are on the rise (3). This can be explained by the fact that the 
genus Aspergillus is one of the most prevalent regarding fungi in several highly 
contaminated occupational environments (4). Since fungi adapt to survive in warmer 
temperatures (5), global warming may further increase the prevalence of fungal disease 
in humans. 
In this context, increasing resistance to the limited arsenal of antifungal drugs is 
a serious public health concern, becoming essential the development of new approaches 
and strategies to tackle antifungal resistance. This includes the assessment of new 
compounds with antimicrobial properties, to be utilized as adjuvants in antifungal 
pharmacologic therapy (6–8). Combination therapy with such compounds has become 
popular in clinical practice as a potential strategy to fight resistant fungal isolates (9). 
Epigallocatechin-3-gallate (EGCG), the main constituent of green tea, has demonstrated 
anti-infective properties in several in vitro studies against bacteria, virus and fungi (10). 
While there has been much research done on Candida spp., information regarding 
EGCG antimycotic activity against Aspergillus fumigatus is scarce. Moreover, as far as I 
know, there is no data available focused on triazole-resistant Aspergillus fumigatus 
strains and the potential synergistic interactions between EGCG and commonly used 
triazole antifungal drugs. 
With this in mind, I aimed to assess the in vitro antifungal potential of EGCG 
against triazole-resistant Aspergillus fumigatus isolates collected during exposure 
assessment campaigns performed in the last ten years in Portugal and abroad in 
different work environments, including waste sorting plants, sawmills, dwellings, 
bakeries, swine farms and taxis, by air sampling and passive sampling using masks, 
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filters, electrostatic dust collector (EDC), among others. I also aimed to assess potential 
synergistic effects between increasing concentrations of EGCG and commonly used 
triazole antifungal drugs, namely itraconazole (ITR), voriconazole (VOR) and 
posaconazole (POS). To accomplish these goals a modification of the European 
Antimicrobial Susceptibility Testing Committee (EUCAST) method “Screening procedure 
E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using 
four-well azole-containing agar plates” (11) was used. 
First of all, an overview of state-of-the-art topics was conducted in Chapter 2. 
“Literature Review”, giving a clear picture of the current knowledge about the Aspergillus 
fumigatus, its azole-resistance mechanisms, the antifungal drugs used against it, and 
the health-promoting effects of EGCG and its potential effects against azole-resistant A. 
fumigatus and other fungi. In Chapter 3. “Methodology” aside from research design and 
sampling methods, I discussed the adaptations made to the EUCAST method used to 
do the present research. The results are presented and discussed in Chapter 4. Finally, 




2. Literature Review 
 
In this chapter I provide an overview of the current knowledge about three main 
topics. I start by exploring the kingdom fungi, narrowing it down to Aspergillus fumigatus 
and its laboratory diagnosis. Then I synthesize the main antifungal agents used against 
this microorganism, also identifying relevant theories that may explain the emergence of 
triazole-resistance among A. fumigatus. Finally, EGCG’s origin, health benefits against 
A. fumigatus and other fungi, but also disadvantages to its medical and dietary use are 
scrutinized. 
2.1. Fungi Classification, Diagnostic and Occupational Burden 
Fungi are eukaryotic organisms that contain a well-defined nucleus, 
mitochondria, Golgi bodies, and endoplasmic reticulum, and are classified in their own 
separate kingdom – Kingdom Fungi. They are distinguished from other eukaryotes by a 
rigid cell wall composed of chitin and glucan and a cell membrane in which cholesterol 
is substituted for ergosterol as the major sterol component (12). Taxonomic classification 
of fungi does not always meet consensus among experts. Until now it was heavily based 
on morphology and mode of spore production, but the advances in genome sequencing 
methodologies have resulted in a revolution in fungal taxonomy based on a phylogenetic 
approach to species recognition that relies on comparative analysis of variable nucleic 
acid characters to define a fungal species. 
Fungi can exist either in a unicellular form (yeast), which can replicate asexually 
by budding or fission and form pseudohyphae or in a multicellular filamentous form 
(mold), which can replicate asexually and sexually. Molds are organisms consisting of 
tubular structures called hyphae (coenocytic or septate) that together produce the 
mycelium. When growing on agar, the hyphae may be termed vegetative or aerial, 
depending if it grows on or above the surface of the culture medium, respectively. The 
latter may produce structures known as conidia (asexual reproductive elements), either 
by blastic (budding) or a thallic process, in which hyphal segments fragment into 
individual cells or arthroconidia. These conidia can become airborne and disseminate 
the fungus. Some fungi of medical importance have a mold form in the environment and 
a spherical form in the body at 37°C – dimorphic fungi (12). 
Fungi reproduce by the formation of spores that may be sexual (meiosis) or 
asexual (mitosis). The form that produces sexual spores is termed the teleomorph (most 
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often in the human body), and the form producing asexual spores is termed the 
anamorph (most often in culture). Asexual spores consist of two types: sporangiospores 
(produced in a containing structure or sporangia) and conidia (borne naked on 
specialized structures) as seen in Aspergillus spp. Sexual reproduction leads to the 
development of ascospores, produced in a specialized saclike structure – the ascus (12). 
2.1.1. Aspergillus spp. 
The fungi belonging to the phylum Ascomycota (Ascomycetes) produce both 
sexual and asexual spores, and account for most of the medically important fungi. This 
phylum is divided in four classes: Pneumocystidomycetes; Saccharomycetes; 
Sordariomycetes; and Eurotiomycetes. The latter comprises several taxonomic orders, 
including the Eurotiales, which contain the teleomorphs of the anamorphic mold genera 
Aspergillus spp. (12). The genus Aspergillus contains about 400 species divided into 8 
sub-genera (Aspergillus, Fumigati, Circumdati, Candidi, Terrei, Nidulantes, Warcupi, and 
Ornati), which in turn are subdivided into several sections or species complexes (13), 
but less than 20 are known to cause disease in humans (14). Aspergillus species are 
saprotrophic fungi that obtain their nutrition by decomposing organic matter, such as 
dead plants or animals, and are widely distributed throughout the environment (15,16). 
2.1.2. Aspergillus fumigatus 
Aspergillus fumigatus, the most common Aspergillus species, is a major 
opportunistic fungal pathogen and often causes disseminated infections in 
immunocompromised hosts, with a relatively high mortality. These includes aspergillosis 
– a broad spectrum of diseases comprising allergies, invasive aspergillosis (IA), 
pulmonary aspergilloma/Chronic Pulmonary Aspergillosis (CPA), and allergic 
bronchopulmonary aspergillosis (ABPA) (17) (see Table 2.1.). Less commonly non-
fumigatus Aspergillus species such as Aspergillus flavus, A. niger, A. terreus, A. clavatus 
and A. nidulans can cause these diseases too (16). All the mentioned species actually 
belong to a species complex that contain morphologically indistinguishable cryptic 
species, some of which may exhibit important antifungal resistance profiles and 
pathogenic features (12), according to molecular taxonomic studies. Aspergillus section 
Fumigati (A. fumigatus complex) contains at least 25 different species, with 7 anamorphs 
other than A. fumigatus itself (18). It is permissible to refer to a fungus only by its asexual 
designation if that is the form usually obtained in culture so, from hereon, it’ll be referred 
to as Aspergillus fumigatus.  
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Table 2.1. Clinical syndromes associated with Aspergillus spp. species 
Type of 
Aspergillosis 






Allergic Rhinitis Nasal obstructions, pleuritis, rhinorrhea, and sneezing   
Allergic Sinusitis 
Occurs when Aspergillus spp. hyphae causes 
inflammation in the sinuses and symptoms of sinus 
infection (drainage, stuffiness, headache), but doesn’t 
cause infection nor tissue invasion. 
(14,19) 
ABPA 
Occurs due to hypersensitive bronchial lumen reaction to 
spore and hyphal surface antigens, which leads to 
persistent inflammation in the lungs and allergy 







Occurs when repeated conidia inhalation leads to 
irreversible lung damage, stimulating antigen-induced 









Occurs when Aspergillus spp. enters the body through a 
break in the skin (e.g., after surgery or burn wound) of 
immunocompromised patients and causes infection, or if 




Occurs when localized cutaneous and subcutaneous 
tissues fungal infection leads to locally invasive tumor-
like abscesses that rupture resulting in ulcers, swelling, 




Occurs when long-term (≥3 months) Aspergillus spp. 
infection forms one or more balls of hyphae plus host 
cells, tissue debris, etc. in cavities (aspergillomas) within 
the lungs, but doesn’t invade surrounding lung tissue. 
(14,19) 
IA 
IA usually affects people who have weakened immune 
systems, such as those who have had an organ or a stem 
cell transplant. It starts from the primary focus of 
infection, which is usually the lower respiratory tract, 
resulting from inhaled spores, though less commonly 
invasion can be via the sinuses or skin through catheter 
insertion sites etc. From the primary focus, Aspergillus 
spp. invades blood vessels and spreads to other organs, 












Inhibits macrophage phagocytosis, as well as T-cell 
activation and proliferation, contributing to A. fumigatus 
virulence in IA patients. 
(14,20) 
Aflatoxins (B1, 
B2, G1, G2) 
Produced by A. flavus, A. parasiticus, and A. nominus. 
May manifest as acute (hepatitis) or chronic disease 
(hepatic cancer), being the most active natural 
carcinogenic substances known. 
(14) 
 
A. fumigatus is a ubiquitous pathogen due to a number of reasons: (i) its ability 
to survive and grow in a wide range of environmental conditions, (ii) its effective dispersal 
in the air, (iii) its physical characteristics that allow conidia to reach the distal airways, 
and (iv) its swift adaptability to the host environment (21). Although A. fumigatus 
optimally grows at 37ºC and a pH 3.7 to 7.6, it can be isolated in the wild wherever 
decaying vegetation and soil temperatures range between 12ºC and 65ºC (21). This 
ability to survive and grow in a wide range of environmental conditions is, in part, due to 
the presence of successful defense systems such as the production of potent secondary 
metabolites (gliotoxin) and efflux pumps (ABC transporters), and the presence of 
melanin in their cell wall, which protects the fungus from ultraviolet irradiation (21). 
Under adverse conditions, A fumigatus produces conidia (spores) on specialized 
hyphal structures called conidiophores, by asexual reproduction (budding from a mother 
cell) (12,16). Ascospores, the propagules produced in the sexual cycle, are produced in 
a structure called ascus under very specific non-physiologic circumstances. The 
ascospores germinate after heating at 70ºC for 30 min, a condition never found on the 
human body, and are therefore unlikely to initiate aspergillosis (12,16,21). A. fumigatus 
conidia are dispersed more efficiently in the air than those of most other molds because 
of the small size of their spores (2-4μm) and their hydrophobic characteristics conferred 
by the surface rodlet layer encoded by the rodA gene (14,21). Once inhaled, airborne 
conidia does not typically colonize de human respiratory tract and are readily cleared of 
the immunocompetent host by cilia on airway epithelial cells and resident alveolar 
macrophages (16). Although fairly uncommon in healthy hosts, A. fumigatus is an 
opportunistic pathogen that generally cause infection when defects in the host immune 
system allow conidia to penetrate, colonize, and reproduce in the host (12). 
Immunodeficiency caused by chemotherapy or immunosuppressive drugs after 
hematopoietic stem cell transplantation; to prevent graft rejection after solid organ 
transplantation; or to treat autoimmune diseases contribute to an increased incidence of 
Aspergillus-related disease. This individuals are unable to clear the lungs from inhaled 
LITERATURE REVIEW 
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conidia that readily germinates into short hyphae known as germ tubes, within 4-6h at 
body temperature, since 37ºC is the optimum temperature for both germination and 
growth (16,21). In such scenarios, the germinated conidia form a colony composed of 
septate multinucleated cells (hyphae) embedded in an extracellular matrix (ECM) to form 
a biofilm. The cells efficiently sense and respond to the altered host environment, 
adapting their physiology by utilizing a coordinated gene expression program that 
enables adaptation to cation (iron, zinc and calcium) limitation, nitrogen and glucose 
deprivation, hypoxic and alkaline stresses, and other unfavorable conditions (16,21). Left 
untreated, hyphae secrete proteases and may invade pulmonary epithelium and 
vasculature, leading to thrombosis and infarction of tissue and to hematogenous 
dissemination to other target organs, particularly the brain (12). 
According to some authors, in patients with high-risk conditions, including stem 
cell and organ transplant recipients, IA (even without azole-resistance) mortality exceeds 
50% (22). An understanding of the occupational hazard posed by Aspergillus spp. and 
an early IA diagnosis can help reduce this burden. 
2.1.3. Laboratory Diagnosis of Invasive Aspergillosis 
Regardless of where the exposure to the conidia takes place, once a person is 
infected, a confirmed diagnosis of IA is only possible with laboratory testing. However, 
getting good answers from the laboratory is dependent upon the quality of the clinical 
sample, specimen selection and collection timing. When selecting specimens for culture 
and microscopic examination, attention should be given to the information obtained from 
clinical examination and radiographic studies. An adequate amount of clinical material 
must be collected aseptically or after proper cleaning and decontamination of the site to 
be sampled, preferably before antifungal therapy is given (12,23). 
Direct microscopy examination is considered the most rapid and cost-effective 
means for the detection of hyphal structures directly in clinical specimens. It serves to 
guide the laboratory in selecting the most appropriate means to culture the specimen 
and is helpful in determining the significance of culture results. A number of different 
stains and microscopic techniques may be used to detect and characterize Aspergillus 
fumigatus directly in clinical samples, but the ones used most often include Gram stain, 
Hematoxylin and Eosin (H&E), Periodic Acid-Schiff (PAS) and Grocott Methenamine 
Silver (GMS) (12). 
Nonetheless, the most sensitive and usually conclusive means of establishing 
the diagnosis of a fungal infection is to isolate in culture the fungus from a patient sample. 
LITERATURE REVIEW 
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When suspected of IA, respiratory samples (sputum, bronchoalveolar lavage, etc) should 
be cultured. General purpose media commonly used for fungal culture is Sabouraud 
dextrose 4% agar (SAB), but selective culture media can be used directly on specimens 
to select the growth of Aspergillus species. After incubation, and if colonies sporulate, 
they should be inspected carefully for presumptive identification to at least genus level 
according to their macroscopic and microscopic morphology (see Table 2.2.) using 
lactophenol cotton blue (24). The detection of invasive fungal infection by blood culture 
in special bottles within an automated system is an important measure in diagnosing IA. 
Although contamination of blood cultures with a fungus may take place, for the most part, 
blood cultures positive for fungi within 5 to 7 days are significant (12). 
 
Table 2.2. Characteristic features of A. fumigatus in clinical specimens and cultures (12) 
Microscopic Morphologic Features in 
Clinical Specimens 
Morphologic Features in Culture 
Macroscopic Microscopic 
Septate, dichotomously branched hyphae 
of uniform width (3-6 μm) 
Blue-green to 
gray 
Conidiophores with enlarged vesicles 
covered with phialides 
Hyphae are hyaline and septate 
 
Until recently, only a positive microbiology culture could truly define a fungal 
infection. However, this could take days, if not weeks. With improved diagnostics now 
available, rapid, sensitive, and specific confirmation of the cause of a fungal infection is 
possible by immunologic, biochemical (serological), molecular (polymerase chain 
reaction [PCR]), and/or proteomic methods of microorganism detection and 
identification. Antigen or antibody tests for Aspergillus spp. may be useful in diagnosing 
infection and allergy but are most important in managing the patient’s response to 
therapy. Commercially available antigen tests are directed against specific Aspergillus-
synthesized and released carbohydrates into body fluids, such as cell wall components 
(galactomannan, 1,3-β-glucans or chitin) or metabolites (D-mannitol) (25). Several test 
formats are used for the detection of antibodies in patient’s serum including 
immunodiffusion enzyme-linked immunosorbent assay or, less commonly, 





The molecular revolution in biology have allowed the for the description of new 
cryptic species among the Aspergillus genera, which are almost impossible to 
differentiate by classic morphological tools and some are more resistant to antifungal 
drugs (13). Alastruey-iziquierdo and colleagues (2012) (13) recommend performing the 
identification of such cryptic species by β-tubulin sequencing or matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) (13), which 
uses species-specific patterns of peptides and protein masses to identify 
microorganisms (12,24). As these techniques cannot detect strains with secondary 
resistance, they also advise performing antifungal susceptibility testing of the isolates 
routinely to assess their antifungal susceptibility profile in vitro, for better management 
of antifungal therapy (13). 
A simple, fast and sensitive diagnosis of IA is key to an early antifungal treatment 
course. Therefore, innovative diagnostic methods may very well contribute to an 
increase in the survival of patients who suffer from this burden. 
2.1.4. Aspergillus fumigatus Occupational Burden 
The presence of fungal species in occupational settings has attracted increasing 
attention, as it represents an occupational burden for workers who are exposed to the 
conidia, increasing risk of infection, especially in those immunocompromised hosts. 
Owing to the A. fumigatus ability to survive and grow in a wide range of environmental 
conditions, is it globally distributed and there have been previous reports of A. fumigatus 
isolated from the air and surfaces of several occupational environments in Portugal and 
abroad. In their study, Viegas et al (2017) (4) reported the highest prevalence of 
Aspergillus spp. were found in wastewater (69,3%) and waste (34,8%) treatment plants 
and poultry feed industry (6,3%), even though it was also prevalent in cork industry 
(0,9%), slaughter houses (1,6%) and swine farms (7,4%) (4). Other studies also found 
wild and resistant A. fumigatus in bakeries (27,28), dwellings, veterinary clinics, dairy 
farms (28), taxis (28,29), industrial sawmills from Norway (30), and captive birds (zoos, 
pets and poultry) from Australia (31); apart, of course, from clinical biological samples 
(sputum, bronchial secretions, bronchoalveolar lavage, pulmonary tissue, etc) and 
hospitals indoor air and surfaces (32,33). 
There are several air and surface sampling methods for fungal assessment. The 
most used direct air sampling method is the Millipore Air Tester using a pre-determined 
flow rate (L/min), and impacted directly onto culture media plates, according to the 
manufacturer’s instructions (4,33). Sampling of settled dust into a sterilized bag (27,33), 
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from filtering respiratory protection devices (FRPD), mechanic protection gloves (MPG) 
or electrostatic dust collector (EDC) comprise the passive sampling air methods (33). 
The latter collection device is increasingly being used because it is electrostatic, 
inexpensive, easy to obtain, and effective at collecting dust (27). As of surface sampling 
techniques, most researchers apply the methods described in the ISO 18593, which 
specifies horizontal methods for sampling techniques using contact plates, stick swabs, 
sponges and cloths on surfaces in the food chain environment (4,33,34). 
2.2. Triazole Antifungal Agents 
Antifungal therapy has undergone a tremendous transformation in recent years. 
Since the mid 1950s, with the domain of the amphotericin B (AMB) and 5-fluorocytosine 
(flucytosine, 5FC), which are toxic and difficult to use, several new, systemically active 
agents and new formulations of older agents with proven antifungal activity have been 
discovered (12). Currently, four antifungal drug classes are used by clinicians for 
systemic treatment of IFI’s: (i) polyenes (AMB), (ii) azoles, (iii) echinocandins and the (iv) 
pyrimidine analogue 5FC (35), each of them with particular targets and mechanisms of 
action. The azole class of antifungals is divided in terms of structure into imidazoles (two 
nitrogens in the azole ring) and triazoles (three nitrogens in the azole ring) (see Table 
2.3.). As A. fumigatus is intrinsically resistant to the commonly used triazole fluconazole 
(FLC) (36), specific first-line antifungal therapy of IA usually involves the administration 
of first-generation triazole – ITR – and/or one or both the second-generation ones – VOR 
and POS – which have improved pharmacological profiles. Triazoles present broad-
spectrum activity but suffer from erratic absorption and have many drug interactions. The 
most common serious side effect, hepatotoxicity, occurs often with VOR in up to 31% of 











Table 2.3. Triazoles Characteristics (12,35) 
























The mechanism of action of triazoles is based on the inhibition of the ergosterol 
biosynthetic pathway by targeting the microsomal cytochrome P450 (CYP450) 
monooxygenase-dependent enzyme – lanosterol 14-α-demethylase (LDM) (see Figure 
2.1.). LDM is encoded by the cyp51A gene in filamentous fungi (35,37) and is essential 
for converting lanosterol to ergosterol, a key component of the fungal cell membrane. 
The demethylation of fungal lanosterol is a two-step process involving the reduced form 
of nicotinamide dinucleotide phosphate and oxygen. As nitrogen from the triazole ring 
binds to the LDM heme iron, oxidation of the lanosterol methyl group is prevented, 
inhibiting the ergosterol production. The accumulation of toxic sterol intermediates, in 
combination with ergosterol depletion, results in the disruption of the cell membrane, 




Figure 2.1. Triazoles mechanism of action (35) 
2.3. Triazole-Resistant Aspergillus fumigatus 
Triazole antifungals have greatly improved survival, however, the emergence of 
triazole-resistant A. fumigatus infections has been growing worldwide and is associated 
with increased treatment failure and mortality. A prospective multicenter international 
surveillance study of azole resistance in A. fumigatus, conducted by Surveillance 
Collaboration on Aspergillus Resistance in Europe (SCARE) network (38), reported a 
prevalence of azole resistance among patients with A. fumigatus species complex 
isolates ranging from 0.0%–26.1% among the centers, settling an overall prevalence of 
3,2% of the total number of strains analyzed. Of the 195 cases with IA, azole-resistance 
was documented in 5,1%, with a case-fatality rate for this cohort of 70%. Yet another 
five-year single-center prospective survey of Aspergillus species isolated from clinical 
specimens in Japan (39) showed a 3% prevalence of azole-resistant isolates, among the 
A. fumigatus. 
Azole resistance is mainly caused by two mechanisms: (i) mutations of the target 
protein and the (ii) overexpression of efflux pumps. Several single-point mutations in the 
cyp51A gene, that lead to amino acid substitutions (single or multiple amino acid 
changes) at codons G54, G138, G448, P216, F219 and M220 have been described 
(2,40). These mutations may directly block the entry or modify the LDM heme binding 
site of the drug, thereby reducing affinity of drug-enzyme interaction (17). However, the 
most common pan-azole-resistance mutations are combinations of tandem repeat (TR) 
sequences of different sizes inserted into the promoter region of cyp51A associated, or 
not, with point mutations in the gene (2), causing significant overexpression of the 
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cyp51A referring with azole resistance (17). It could be either amino acid changes of 
tyrosine to phenylalanine at codon 121 and threonine to alanine at codon 289, coupled 
with a TR of a 46-base pair (bp) sequence in the promoter region (TR46/Y121F/T289A) 
(41,42); a 34-bp-long TR in the promoter region associated with a leucine-to-histidine 
substitution in codon 98 (TR34/L98H) (43), which is associated with an 8-fold increase in 
the gene expression (36); or even a single 53-bp long TR in the promoter region (TR53) 
with no mutations in the cyp51A gene (40,42). 
Several reports show a predominance of the TR34/L98H mechanism. The 
previously mentioned SCARE study (38) reported a 48,9% prevalence. This mechanism 
was present in 30 of 32 (94%) ITR resistant isolates of Snelders et al (2008) study (43). 
Another report by van der Linden et al (2013) (42) stated that 47 of 63 patients (74.6%) 
harbored the TR34/L98H resistance mechanism and only 13 patients (20.6%) the 
TR46/Y121F/ T289A (42). In Portugal, the first report of environmental isolates bearing 
the TR34/L98H mutation, isolated from occupational environments, was published in 
2021 (33). 
Overexpression of efflux pumps account for the majority of the non-cyp51-
mediated azole resistance. Many important efflux pumps belong to adenosine 
triphosphate (ATP)-binding cassette (ABC) transporters (AtrF and AtrI) or members of 
major facilitator superfamily (MFS) – MdrA (16,17). ABC transporters are composed of 
two transmembrane and two cytoplasmic nucleotide-binding domains, and use ATP to 
pump azoles and/or toxic metabolites out of the fungal cell (2), and MFS proteins cross 
the cell membrane by proton gradients (17). Increased expression of transporters is also 
associated with phenotypic resistance in A. fumigatus, since there is a decreased 
amount of intracellular drug available to bind to its target. 
Two hypotheses have been proposed to explain the origin of triazole resistance. 
It could be due to (i) improper use of triazole drugs to treat sick people in clinical settings 
(e.g., when dosages are too low, or when treatment courses are not long enough), or 
even when antifungal drugs are used properly for long periods of azole treatment and 
prophylaxis – “non-fungicide-driven” resistance mechanisms (1,2). It could have also 
arisen (ii) from the extensive use of triazole fungicides in agriculture to prevent and treat 
fungal diseases in crops – fungicide-driven resistance mechanisms (1). The use of 
triazole fungicides in agriculture is associated with TR-mediated resistance mechanisms 
(2). Astoundingly, the use of certain azole fungicides, which were shown to induce the 
TR46/Y121F/T289A resistance mechanism (41), was approved in Europe in the 1990s, 
and only 10 and 20 years later the first clinical isolate harboring the TR34/L98H (43) and 
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TR46/Y121F/T289A (42) mutations were described, respectively. This environmental 
stress led to natural selection of triazole-resistant A. fumigatus in the environment which 
is able to infect the susceptible population (43). Several reported cases of triazole-
resistant IA developing in triazole-naïve human patients (2) support the environmental 
origin. This fungicide-driven mechanism is thought to be widespread worldwide (44). 
To distinguish whether microorganisms are resistant to antifungals or not, the 
EUCAST established limit values expressed as minimum inhibitory concentrations 
(MIC’s), indicating the minimum concentration of the drug that inhibits the growth of fungi. 
According to the most recent EUCAST (45) definition, a microorganism can be 
categorized as “S” (susceptible under standard dosing regimen), “I” (susceptible to 
increased exposure by adjusting the dosing regimen or its concentration) or “R” (resistant 
even when there is increased exposure) (45). Several in vitro studies have reported that 
triazole-resistant A. fumigatus harboring any of the above-mentioned resistance 
mechanisms, show elevated EUCAST MIC values against all triazoles (see Table 2.4.). 
Importantly, TR-mediated mechanisms confer resistance to all mold-active medical 
triazoles without incurring a fitness cost or survival disadvantage to the fungus (22). 
 
Table 2.4. In vitro susceptibility profile of azole-resistant A. fumigatus isolates to triazoles 
MIC Breakpoints (μg/mL) 
Mutation Ref. 
ITR VOR POS 
1 1 0,125 wild type (46) 
8 8 1 TR46/Y121F/T289A 
(41) 
4 8 1 G448 
2 >16 0,5 TR46/Y121F/T289A (42) 
8 4 1 TR34/L98H (33) 
>8 >8 >1 TR46/Y121F/T289A (47) 
Values determined by the EUCAST standardized broth microdilution method are shaded 
 
As mentioned earlier, IA mortality exceeds 50%, even in patients infected with 
azole-sensitive A. fumigatus (22). Triazole antifungals have greatly improved survival, 
however, triazole-resistant A. fumigatus infections are increasingly reported worldwide 
and are associated with increased treatment failure and mortality rates reaching an 
outstanding 88% for patients with triazole-resistant IA (48). The poor outcome for this 
patients, along with the common serious side effects, namely hepatotoxicity, that occurs 
most often with VOR (in 31% cases) (35), and the increasing resistance to the limited 
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arsenal of antifungal drugs make the assessment of new compounds with antimicrobial 
properties, an imperative matter to tackle the antifungal resistance crisis. 
2.4. Epigallocatechin-3-gallate 
EGCG is the most abundant (~60%) and active green tea catechin (49). Tea is 
one of the oldest and most popular beverages consumed across the world. All teas come 
from the leaves of the same plant (Camellia sinensis), that is mainly grown in sub-tropical 
regions such as Japan, China and Taiwan (50). There are four main types of tea 
produced, determined by how the tea leaves are processed, specifically by drying and 
fermentation methods – green, white, Oolong, and black tea. Green tea is produced 
when the mature leaves are picked up, quickly dried and applied heat to prevent any 
fermentation and preservation of polyphenols (49,51). White tea is processed the least 
and uses very young leaves and leaf buds. Oolong tea is produced by partially 
fermenting the leaves, and black tea by fully fermenting them (52). The chemical 
composition of green tea includes an extensive range of compounds (50), but the ones 
who account for the aroma and health benefits of green tea are the polyphenols (53). 
The most pertinent polyphenols are the flavonoids and in turn catechins, that comprise 
80-90% of the flavonoids and around 30-40% of the water-soluble solids in green tea 
(52,54). These polyphenols are present in much higher concentrations in green tea than 
black, white or oolong tea (50,53), mainly because of the way it is processed after 
harvesting. Among the varieties and brands of green tea infusions and green tea extracts 
consumed, there is some variation in catechin content due to a number of factors such 
as growth conditions, processing techniques and brewing temperature and length (52). 
Among the biologically active compounds contained in C. sinensis, catechins 
stand out since they exhibit several health-promoting properties. Catechins contained in 
tea include epicatechin, epigallocatechin, epicatechin-3-gallate, and epigallocatechin-3-
gallate (EGCG) (50). The latter is the most abundant (~60%) and active one (49). The 
basic structure of catechins involve a gallate moiety, esterified at the 3rd position of the 
C ring, a catechol group (3,4,5-tri- hydroxy groups) on the B ring, and hydroxyl groups 
at the 5th and 7th positions on the A ring (see Figure 2.2.) (54). The antioxidant activity 
potential of catechins depends mainly on the chemical structure, specifically on the 
number of hidroxyl groups and their distribution (50). The more hydroxyl groups, the 
more effective a free radical scavenger the catechin becomes. The structure of EGCG 
is an ortho-benzoyl benzopyran derivative, which has more hydroxyl bases than its 
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counterparts. Therefore, EGCG has the potential ability to scavenge free radicals 
because of the presence of the C ring gallate group (54). 
Figure 2.2. Chemical structure of the catechin components in green tea (54) 
2.4.1. Health-Associated Effects of EGCG 
Extensive research has shown that catechins – particularly EGCG – have a wide 
range of health-related benefits and therapeutic potential against various human 
diseases (see Table 2.5.).  
 
Table 2.5. Health benefits of EGCG 
Health Benefit Mechanism of Action Ref. 
Antioxidant 
The phenolic hydroxyl group provides hydrogen and undergoes oxidation 
reactions, scavenging reactive oxygen species (ROS)  
(54,55) 
Anti-neoplastic 
Inducing apoptosis by inhibition of the nuclear factor erythroid 2-related 
factor 2 (Nrf2) signaling pathway 
(55) 
Downregulation of PI3K/AKT, NF-κB, and Wnt signaling pathways, to inhibit 
cellular proliferation and inflammation and induce apoptosis 
Protection against epithelial-mesenchymal transition (EMT) via an increase 
in the expression of E-cadherin, suppressing cell metastasis 
Anti-
inflammatory 
Suppression of NF-κB activation, downregulating expression of 
inflammatory cytokines and inflammation-related enzymes including TNF-







Downregulation of genes involved in the synthesis of de novo fatty acids 
(acc1, fas, scd1, c/ebpβ, pparγ, and srebp1) and upregulation of genes 
associated with lipolysis (hsl) and lipid oxidization in adipose tissue of mice 
(57) 
Anti-diabetic 
Stimulation of glucose uptake in response to insulin, by increasing 
expression of antioxidant enzymes (SOD, GPx) and phosphorylation of 




Attenuation of salt-sensitive hypertension via anti-oxidant, anti-
inflammatory, and apoptosis-inducing effects on fibroblasts mediated by 67 




Improves sperm motility and viability and enhances oocyte and embryo 
quality, as well as fertilization and clinical pregnancy rates in females 
(54) 
 
2.4.2. Anti-infectious Effects of EGCG 
Besides those broad health benefits, EGCG has also been shown to have 
specific anti-infectious properties and thus effective against a number of viruses, 
parasites, bacteria, fungi, and even prions. These topics are discussed next. 
EGCG acts against virus by (i) inhibiting the virus from binding to and entering 
host cells; (ii) inhibiting viral RNA and DNA synthesis and viral gene transcription; (iii) 
destroying and functionally altering various viral molecules; and (iv) preventing infection 
with viruses in human and animal patients. Concerning prions, EGCG inhibits the 𝛽-
sheet prions from changing the 𝛼-helical forms and could induce reversal of the 𝛽-sheet 
forms back to 𝛼-helical forms (52). Most studies showed antiviral properties within 
physiological concentrations of EGCG in vitro (10). Table 2.6. exemplifies some of the 
antiviral properties of EGCG against different viruses and prions, its mechanisms of 
action and MIC’s necessary for either virustatic or virucidal activity. 
 
Table 2.6. Antiviral properties of EGCG 
Microorg. Mechanism of Action MIC’s Effect Ref. 
HIV Type-1 









Inhibits the lytic infection of EBV by decreasing the 
phosphorylation, and therefore suppressing, the 







Hepatitis B  
Virus 
After treatment for 6 d, EGCG significantly inhibits 








EGCG binds to several regions within the 
unstructured N domain preventing the acquisition of 
β-sheet structure of select Sup35 prion strains. 
nd Virustatic (63) 
nd, not defined 
 
Some interesting completed and ongoing clinical trials regarding the effects of 
EGCG against influenza virus have revealed that green tea catechins are able to prevent 
influenza infection. A randomized, double-blinded, placebo-controlled trial of 200 
healthcare workers showed that the incidence of clinically defined influenza infection was 
significantly lower in a catechin capsules-given group (4.1%) compared with the placebo 
group (13.1%) (64). Another observational study found that green tea consumption is 
inversely associated with the incidence of influenza infection among schoolchildren in a 
tea plantation area of Japan (65). These results suggest that taking green tea and green 
tea catechins may be effective prophylaxis for influenza infection. 
As with viruses, EGCG can also be used to difficult the parasite infection by (i) 
decreasing the number of parasites and its growth; (ii) fragmenting the parasite DNA or 
(iii) reducing their fatty acid synthesis (52). Studies with parasites include Plasmodium 
falciparum, Babesia spp., Trypanosoma spp., and Leishmania braziliensis. Several 
reports address the properties of EGCG against different parasites (see Table 2.7.). 
 
Table 2.7. Antiparasitic properties of EGCG 
Microorg. Mechanism of Action MIC’s Effect Ref. 
Babesia bovis 
& B. bigemina 
Growth of B. bovis and B. bigemina was 
inhibited at 10 and 25 μM respectively and 









EGCG exerts its effects on acetyl-CoA 
carboxylase (ACC) through activation of 
AMP-dependent protein kinase, which 
phosphorylates and inhibits T. brucei ACC 
and fatty acid synthesis. 
EC50 of 37 μM and 
55 μM for 
bloodstream form 
and procyclic form 
Parasitistatic (67) 
     






Green tea extract (25–100 μM EGCG) 
inhibits the growth of P. falciparum culture, 
by interfering with uptake of exogenous 
iron and depleting the intracellular labile 
iron pool in the red blood cells, leading to 
inhibition of their growth. 







EGCG promotes ROS production, 
resulting in decreased mitochondrial 
membrane potential (∆Ψm) and reduced 
intracellular ATP concentrations. 
Reduced 
promastigote 
viability and the 
infection index with 
IC50 of 278.8 μM 
and 3.4 μM  
Parasiticidal (69) 
 
The kingdom bacteria is the main focus of EGCG studies concerning 
microorganisms. This may be due to the worldwide awareness raised by the world health 
organization about antibiotic resistance and/or the “ease-of-use” of these 
microorganisms in experimental in vitro studies, compared to other microorganisms like 
fungi. Reygaert et al (2018) (52), reviewed the possibilities for the use of green tea 
catechins in treating and preventing infectious diseases and realized that EGCG can 
successfully interfere with several bacterial processes due to its ability to bind to bacterial 
cell membranes (52). Such ability can lead to cell membrane damage, resulting in cell 
lysis; loss of function of transmembrane transporter proteins, like the pumps responsible 
for the efflux of toxins and antimicrobial agents; loss of bacterial ability to bind to host 
cells; and loss of the ability for quorum sensing and biofilm formation. Besides this 
capability, EGCG also affects basic bacterial functions such as fatty acid and folate 
biosynthesis pathways, by targeting different proteins; bacterial DNA gyrase and ATP 
synthase activities, by binding to the ATP binding site of the gyrase B subunit (70); and 
bacterial tyrosine phosphatase and cysteine proteases (52). Table 2.8. synthesizes 
some research papers reporting antibacterial properties of EGCG, as well as MIC’s 








Table 2.8. Antibacterial properties of EGCG 
Microorg. Mechanism of Action MIC’s Effect Ref. 
Escherichia 
coli 
Exposure of E. coli cells to EGCG induces an 
adaptive oxidative stress response resulting in 
an increase in intracellular ROS. 
100-1000 μM Bactericidal (71) 
Bacillus 
subtilis 
EGCG inhibits the function of several 
membrane proteins in cell envelope, including 
the oligopeptide ABC transporter (Oppa), PTS 
system transporter, phosphate ABC trans- 
porter, and PBP5. 





EGCG inhibits biofilm formation (MIC50=7,8 
μg/mL) and reduces viability (MIC50=156,25 
μg/mL) of the preformed biofilm. EGCG at 
15,6 μg/mL suppressed expression of atpD, 











EGCG damages the bacterial cell wall and 
interferes with the chelation of iron. It prevents 
biofilm formation at concentrations that did not 
interfere with bacterial growth (62,5 μg/mL) 
and decreases pre-formed biofilm viability 
(1000 μg/mL, time-dependent). It also 
decreases the adherence of F. nucleatum to 
epithelial cells and matrix proteins (31,25, 
62,5 and 125 μg/mL, dose-dependent) and 
attenuated F. nucleatum-mediated hemolysis 
by 67% (125 μg/mL) and hydrogen sulfide 










For the purpose of this study, there’s a need to emphasize the antifungal activity 
of EGCG. Most research papers mostly focus on the antifungal effects of this compound 
against Candida species. This may be due to the fact that candidiasis and candidaemia 
pose a much higher overall burden to public health than infections by other fungi such 
as Aspergillus spp. Actually, in a meta-analysis of population-based studies, the 
European incidence of candidaemia alone was approximately 79 cases per day, of which 
29 patients might have fatal outcome at day 30 (75).  
A study by Chen, et al (2015) (76) investigating the susceptibility of Candida and 
A. fumigatus species to different teas and EGCG isolated from green tea using the 
EUCAST microdilution method, showed potent in vitro antifungal activity of all teas and 
EGCG against C. glabrata, but none had effect on A. fumigatus at the concentrations 
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tested. The MIC50 of EGCG were 0.31 μg/mL against C. glabrata and 5 μg/mL against 
C. albicans and C. parapsilosis. At higher concentrations EGCG was fungicidal against 
C. glabrata (76). Hirasawa and Takada (2004) (7), in another study regarding C. 
albicans, noted it was sensitive to EGCG in a pH-dependent manner. EGCG was more 
active at slightly basic pHs. At pH 6.0 the MIC90 was 2000 μg/mL, while it ranged from 
500–1000 μg/mL at pH 6,5 and as low as 15.6–250 μg/mL at pH 7.0 (7). The results from 
another investigation by Park, et al (2006) (77) evaluating the in vitro antifungal 
susceptibility of 21 clinical isolates of seven Candida species to EGCG and commonly 
used antifungal agents, using the Clinical and Laboratory Standards Institute (CLSI) 
protocol M27-A, were mainly in agreement with those obtained by Chen, et al (2015) 
(76) and Hirasawa and Takada (2004) (7). Among the tested species, C. glabrata 
exhibited the highest susceptibility to EGCG (MIC50, 0.5–1 μg/mL and MIC90, 1–2 μg/mL), 
while C. albicans (MIC50, 4–8 μg/mL and MIC90, >16 μg/mL) and C. parapsilosis (MIC50, 
1–4 μg/mL and MIC90, 2–16 μg/mL) were also susceptible to EGCG, although less than 
C. glabrata (77). A few years after reporting inhibitory effect of EGCG on clinical isolates 
of Candida species, Park et al (2011) (78) investigated the in vitro antifungal activity of 
EGCG and antifungal agents against clinically isolated dermatophytes (M. canis, T. 
mentagrophytes, and T. rubrum), by the CLSI M38-A2 method. As expected, the 
dermatophytes isolates also revealed lower MIC values against FLC (MIC50, 2-16 μg/mL, 
MIC90, 4-32 μg/mL, and geometric mean (GM) MICs, 3.45-25.8 μg/mL) and 5FC (MIC50, 
MIC90, and GM MICs, >64 μg/mL) than EGCG (MIC50, 2-4 μg/mL, MIC90, 4-8 μg/mL, and 
GM MICs, 3.36-4 μg/mL), although they were less susceptible to AMB and ITR (78). 
More recently, Behbehani et al (2019) (79) examined the efficacy of EGCG and in 
combination with FLC/ketoconazole (KET) drugs against oral Candida isolates. The MIC 
ranges of EGCG alone, determined using the M27-A CLSI protocol, were between 3.91 
to 15.63 mg/mL against all Candida isolates, higher than the MIC ranges of FCZ and 
KET (4 to 128 mg/mL and 4 to 32 mg/mL, respectively). Overall, the concentrations of 
EGCG for antifungal susceptibility in the published reports were slightly higher than those 
of tested antifungal agents (FLC, AMB, 5FC, ITR and KET), suggesting that EGCG may 
be effectively used as a possible agent or adjuvant for antifungal therapy in candidiasis 
and dermatophytosis. 
Although proved that EGCG has antifungal potential against Candida spp. and 
dermatophytes, its mechanism of action remained unclear until 2006, when Navarro-
Martínez et al (8), demonstrated that EGCG can indirectly disrupt ergosterol production, 
by inhibiting the C. albicans dihydrofolate reductase – a key enzyme in the biosynthesis 
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of purines, pyrimidines and several amino acids. The authors also determined the MIC 
values of EGCG for the strains tested at pH 7.4 by the CLSI broth dilution M27-A method, 
which varied from 1 to 32 μg/mL, falling within the range of previous reports (8). Later, 
Evensen and Braun (2009) (80) conducted experiments to determine the effects of tea 
polyphenols on C. albicans biofilm formation. Results showed that cultures treated with 
1.0 mmol/L EGCG, displayed a 75% reduction of viable cells during biofilm formation, 
and that pre-established biofilms treated with EGCG were also reduced, by 80%. The 
authors demonstrated that in vivo proteasome activity was significantly decreased, 
contributing to cellular metabolic and structural disruptions, inhibiting of biofilm formation 
and maintenance by C. albicans (80). 
2.4.3. Antifungal Synergism 
Since EGCG alone is proved to have health beneficial properties, researchers 
have also been assessing the potential synergism of this compound in combination with 
other medically used drugs. Although research about drug synergism concerning EGCG 
have been primarily focused on a variety of drugs other than antifungals (81–84), 
antifungal effects of EGCG and other phytocompounds on Candida species alone and 
in combination with medically used antifungal agents have been attracting considerable 
attention, specifically on enhancing its susceptibility to those agents. Antifungal 
synergism is the combination of antifungal agents that have enhanced antifungal activity 
when used together compared with the activity of each agent alone (12). 
Da Silva and colleagues (2014) (6) evaluated in vitro interactions of EGCG with 
FLC against FLC-resistant Candida tropicalis. Results show that EGCG alone had no 
antifungal activity within the concentration range tested, but when the FLC-resistant 
strains were exposed to various concentrations (0.25 to 128 μg/mL) of EGCG combined 
with various FLC concentrations (0.25 to 16 μg/mL), there was significant synergistic 
activity. All studied strains showed MIC50 values of 64 μg/mL to FLC, that came down to 
16 μg/mL after cotreatment with 128 μg/mL of EGCG (6). In the Hirasawa and Takada 
(2004) (7) study, the authors also noted that various catechins present in green tea, 
including EGCG, have significant antifungal activities when combined not only with FLC 
but also AMB, indicating additive or synergistic effects. The research performed by broth 
dilution showed that combined treatment with 3.12–12.5 μg/mL EGCG plus AMB 0.5 
μg/mL markedly decreased the growth of AMB-resistant C. albicans. Astonishingly, the 
combined use of 12.5 μg/mL EGCG and 10–50 μg/mL FLC inhibited the growth of FLC-
resistant C. albicans by an impressive 98.5%– 99.7% (7). 
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Behbehani et al (2019) (79) research results were mainly in agreement with those 
obtained earlier in a sense that the combination of EGCG (MIC 3.91-15.63 μg/mL) with 
FLC or KET against the planktonic cells of all Candida isolates showed a remarkable 
decrease in the MIC values (MIC of FLC decreased from 4-64 to 1-8 μg/mL; MIC of KET 
decreased from 4-32 to 1-8 μg/mL) compared to each drug alone. Concerning Candida 
biofilm cells, the minimum biofilm inhibitory concentration (MBIC) ranges of EGCG 
against all tested isolates were between 62.5-125 μg/mL and in the range of 128-512 
μg/mL (FLC) and 64 to 512 (KET) μg/mL, but when EGCG was combined with FLC or 
KET drugs, the MBIC values of drugs and EGCG decreased 3 to 5 fold indicating a 
synergistic effect in almost all the cases (79). Anand and Rai (2016) (85), who also 
evaluated synergistic effects of catechins isolated from green tea leaves with FLC and 
AMB against C. albicans and C. glabrata, showed synergistic activity with FLC and AMB 
against Candida species. The MIC90 values of FLC (64-128 μg/mL), AMB (1 μg/mL), 
green tea catechins (125-250 μg/mL) and EGCG (125-250 μg/mL) alone proved lower 
when the catechins and EGCG were used in combination of FLC or AMB. FLC MIC90 
values ranged from 4-64 μg/mL, AMB’s from 0.06-2 μg/mL, green tea catechins from 
15.62-62.5 μg/mL, and EGCG’s from 7.81-62.5 μg/mL. It is important to note that not all 
the purified catechins isolated from different green tea leaves had synergistic activity 
with FLC and AMB against C. albicans, but all have demonstrated synergistic inhibitory 
potential with AMB against C. glabrata (85). 
As the results from in vitro experiments clearly suggested that EGCG and other 
phytocompounds could be an effective treatment or cotreatment for Candida spp. 
infections, Han (2007) took the leap from in vitro to in vivo experiments. He investigated 
synergic anticandidal effects of EGCG and its mechanism in a murine model of 
disseminated candidiasis caused by C. albicans and found that EGCG-given BALB/c 
mice inoculated with viable C. albicans yeast cells survived longer than the control mice 
group. EGCG treatment inhibited the hyphal formation, causing growth-inhibition of the 
Candida cells. In experiments determining synergic effects, mice given diluent (control), 
AMB (0.5 mg/kg of body weight), or EGCG (2 mg/kg) had mean survival times (MST) of 
approximately 10.9, 11.7, and 13.9 days, respectively. However, mice administered with 
a combination of AMB (0.5mg/kg) plus EGCG (2 mg/kg) had an MST value of up to 42.1 
days, surviving an average of 30 days longer than the mice who received AMB alone. 
Actually, the MST from the combination-treated mice groups was much higher than MST 
from mice group that received four times the AMB dose. These results indicate that 
EGCG, which has in vitro and in vivo anticandidal activity by blockage of the hyphal 
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formation, presents synergistic effects against disseminated candidiasis when combined 
with AMB (81). 
Confirmed the in vitro and in vivo anticandidal and synergistic effects of EGCG, 
it was time to translate all this knowledge to clinical trials. Recently, a randomized double-
blinded controlled clinical trial was designed to evaluate and compare the antimicrobial 
efficacy of, among others, green tea mouth rinses against oral Candida albicans in 
children. Unfortunately, the efforts came unfruitful, as a statistically significant fall in 
colony count was not found (86). 
2.4.4. Disadvantages of EGCG 
Despite all the evidence pointing to the health benefits of EGCG, there are two 
major downsides to its possible medical and dietary use worth considering. First of all, 
EGCG alone suffers from poor in vivo bioavailability and stability (49). When consumed, 
EGCG is at higher concentration in the digestive system, but the issue of its 
bioavailability comes from the extreme pH conditions in the stomach and intestinal tract, 
as well as related digestive enzymes and biologically inactivating processes such as 
methylation (55,87). The main reason for low absorption rate of EGCG is because it is 
transported across intestinal epithelium predominantly by passive diffusion, and there is 
no specific receptors on the surface of small intestinal epithelial cells that have been 
found to carry EGCG into cells (87). Emerging technologies such as nanotechnology 
can, in part, provide solutions to encounter some of these limitations. For this reason, 
EGCG is mostly used either in combination with other components such as nanoparticles 
(88); encapsulated in edible coating with royal jelly proteins (89); or being modified as a 
prodrug (90) to enhance its stability and bioavailability. Cai et al (2018) (87) conducted 
a thorough review on the advances in bioavailability studies involving absorption and 
metabolic biotransformation of green tea catechins. 
Secondly, there have been reports of hepatotoxicity linked to the consumption of 
large amounts of green tea extracts (91). After the report of 13 cases of hepatotoxicity, 
a green tea preparation (Exolise®) marketed for weight loss, was withdrawn in 2003. 
More recently SLIMQUICK® weight loss products, many of which contain green tea 
extract, have been associated with six cases of acute liver injury. Following concerns 
regarding their possible harmful effects on the liver, the European Food Safety Authority 
(EFSA) (91) has assessed the safety of green tea catechins from dietary sources. For 
green tea infusions brewed with hot water, and instant and ready-to-drink green tea 
beverages with similar catechin content, EFSA’s experts concluded that there is 
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generally no indication of liver damage in the range of the mean daily intake of EGCG 
(90–300 mg/day), nor after high consumption of ≥ 5 cups per day (300–866 mg/day), 
and that the few cases of liver damage reported in humans are likely due to rare and 
unpredictable reactions. Concerning food supplements, EFSA’s panel concluded – on 
the basis of human interventional clinical trials conducted with volunteers under medical 
supervision – that there was no indication of hepatotoxicity for doses below 800 mg/day 
taken for up to 12 months (91). According to these results, about seven cups of green 
tea correspond to the highest amount that could be drunk without expecting health 
consequences (92). 
 
Despite of the fact that, as stated before, most of the in vitro and in vivo data on 
the EGCG antifungal activity were assessed against Candida species and suggested its 
potential as additional or co-adjuvant therapeutic agent, further research is crucial to 
evaluate antifungal activity of EGCG against a number of different fungi such as 
Aspergillus spp, and other clinically relevant fungi. In this sense, this study fills a gap in 
the existing knowledge and pushes the boundary of scientific evidence. As far as I know, 
this is the first research focusing on the in vitro antifungal effects of EGCG both alone 
and in combination with different antifungals, namely ITR, VOR and POS, against 
triazole-resistant Aspergillus fumigatus. The ultimate goals when testing EGCG’s anti-
Aspergillus potential are (i) to enhance efficacy in the treatment of triazole-resistant IA 
infections, (ii) to broaden the spectrum of empiric antifungal therapy available, (iii) to 
lower the dosages of triazoles, thus preventing adverse effects and the emergence of 
triazole-resistant A. fumigatus, and/or (iv) to enhance the antifungal effects by achieving 










In this chapter it is described exactly how I collected and analyzed the data, as 
well as the overall approach designing this experiment. 
3.1. Research Design and Location 
This research took place in Lisbon School of Health Technology facilities, a part 
of Lisbon Polytechnic Institute, in collaboration with Health & Technology Research 
Center. It is classified as experimental and interventional (since the researcher play an 
active role by manipulating the EGCG and antifungal concentrations, to evaluate the 
effect of this intervention upon the presence or absence of fungal growth); with a factorial 
design (since more than one independent variable, each comprising at least two levels 
– absence or presence in different concentrations – are used to verify the combined 
action exerted by the independent variables on the dependent one) (93). 
3.2. Variables 
For data analyze and reproducibility purposes, the screening procedure was 
made in triplicate. The independent variables, the ones manipulated by the researcher, 
are the concentrations of EGCG, ITR, VOR and POS. The dependent variable, on which 
the effects of the independent variables are exerted, is the presence or absence of fungal 
growth on each plate. The former is classified as quantitative and the latter as qualitative 
of nominal scale, since the results were read visually by recording the presence or 
absence of growth on each plate (93). 
3.3. A. fumigatus Isolates Characterization 
The triazole-resistant A. fumigatus isolates (N=3) were previously studied and 
kindly provided by Doctor Carla Viegas, from H&TRC. These isolates came from a bank 
of Aspergillus fumigatus isolates collected in previous exposure assessment campaigns 
performed from January 2018 to February 2019 in different Portuguese indoor and 
occupational environments. Isolate number 299 was collected from the air of a dairy, 
while isolates number 873 and 1209 came from a waste sorting plant FRPD. Aspergillus 
species were identified at section level by macroscopic and microscopic morphology 
using a tease mount or Scotch tape mount and lactophenol cotton blue mount 
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procedures and using identification atlas (94). A. fumigatus isolates were confirmed by 
molecular methods (sequence analysis of the calmodulin or β-tubulin genes for 
Aspergillus spp.), and sequencing of the cyp51A gene and its promoter revealed pan-
azole-resistance mutations in all three isolates (33). Table 3.1. synthesizes the growth 
pattern of these isolates as well as their MIC’s and cyp51A mutation mechanism, 
obtained by Gonçalves et al (2021) (33). As positive control, an azole-sensitive A. 
fumigatus isolate was obtained from reference strains from the Mycology Laboratory of 
the National Institute of Health Doctor Ricardo Jorge (INSA). 
 
Table 3.1. Growth pattern of the triazole-resistant A. fumigatus isolates, their MIC’s and 
mutations found on the cyp51A gene (33) 
Isolate 
Azole Screening Media MIC’s (μg/mL) 
cyp51A Mutation 
VOR POS ITR VOR POS ITR 
299 + + + 4 2 4 
TR34/L98H 873 + + + 2 1 4 
1209 - + + 4 1 8 
-: negative (no growth); +: positive (any type growth) 
3.4. Screening of Azole Resistance and evaluation of EGCG effect in 
Aspergillus fumigatus Isolates 
I set to answer our research question through the adaptation of the EUCAST 
method “Screening procedure E.Def 10.1 for the detection of azole resistance in 
Aspergillus fumigatus isolates using four-well azole-containing agar plates” (11). It was 
modified intending the phenotypic detection of A. fumigatus isolates resistant to ITR, 
VOR and POS, as well as the detection of synergism between EGCG and the triazoles. 
3.4.1. Preparation of Stock Solutions 
The ITR (Acros Organics, 452870050), VOR (Honeywell, 137234-62-9), POS 
(Sigma-Aldrich, 32103) and EGCG (Sigma-Aldrich; E4143) powders were weighed on 








Azole stock solutions were prepared in DMSO as follows: 
1. For 500 mg/L solution with final volume of 10 mL, 5.1 mg of ITR (kept at 4ºC), 5 
mg of VOR (kept at room temperature) and 5 mg of POS were weighted; 
2. 10 mL of DMSO were added in a sterilized falcon and stirred until dissolved; 
3. The azole stock solutions were kept at -80ºC (valid for 6 months without 
significant loss of activity). 
 
EGCG stock solution was prepared in sterile water as follows: 
1. For 5000 μg/mL solution with final volume of 1 mL, 5 mg (=0.005g) of EGCG 
(kept at 4ºC) were weighted; 
2. 1 mL of sterile water was added in a sterilized Eppendorf and vortexed until 
dissolved; 
3. The EGCG stock solution aliquots were kept at -20ºC and away from any light 
source since EGCG is light sensitive. 
3.4.2. Media 
For the purpose of this study it was used the Lonza BioWhittaker® (04-525F) 
selective media RPMI-1640 (with L-Glutamine and buffered with 3-(N-morpholino) 
propane-sulfonic acid [MOPS], at a final concentration of 0.165 mol/L, pH 7.0., but 
without sodium bicarbonate) supplemented with glucose to a final concentration of 2% 
(RPMI 2% G), as well as the VWR Chemicals BDH® (84663.0500) Sabouraud dextrose 
4% agar, a general-purpose media for the cultivation and isolation of pathogenic and 
non-pathogenic fungi. 
3.4.3. Preparation of Azole-Containing Plates 
The azole-containing RPMI-1640 plates (nominal capacity of approximately 20 
mL and 100 mm) supplemented with chloramphenicol (at a final concentration of 0.2 
mg/mL) were prepared as follows: 
1. Azole stock solution was defrosted in advance at room temperature; 
2. D(+)-Glucose (Millipore, 1.08337.0250), Agar Bacteriologic (Frilabo, 61101) and 
Chloramphenicol (Fisher-Scientific, BP904-100) were dissolved in 900 mL of 
RPMI-1640 medium (see Table 3.2.); 
3. Components were stirred until completely dissolved and then filled up to 990 mL 
with RPMI-1640 medium; 
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4. The solution was poured in 4 Erlenmeyer flasks (247.5 mL in each flask) and 
autoclaved at 121ºC for 15 minutes; 
5. Agar was let to cool down until one was able to touch the flasks comfortably; 
6. The different azole stock solutions were added to each flask (see Table 3.2.) and 
the remaining antifungal-free flask was used for the growth control plates, as 
follows: 
• Erlenmeyer 1: ITR (final concentration, 4 μg/mL) 
• Erlenmeyer 2: VOR (final concentration, 2 μg/mL) 
• Erlenmeyer 3: POS (final concentration, 0.5 μg/mL) 
• Erlenmeyer 4: growth control (antifungal-free plate); 
7. The agar from each flask was poured (approximately 20 mL per plate) to the 
respective sterile plates and let to solidify; 
8. The plates prepared were properly sealed and stored at 4ºC for up to 1 month 
from the date of preparation if there was no reduction in the height of agar 
(suggesting evaporation). 
 
Table 3.2. Reagents to prepare 1 L of RPMI-1640 (~50 agar-containing plates) 
Reagents Mass Weighted/Volume Pippeted 
RPMI-1640 (with L-Glutamine and 0,165 M MOPS 
Without Sodium Bicarbonate)a 
10.4 g 
D(+)-Glucoseb 18.0 g 
Agar Bacteriologicalc 20.0 g 
Chloramphenicold 0.180 g (final concentration: 0.2 mg/mL) 
ITRe (stock solution) 1.980 mL in 247.5 mL of agar 
POSf (stock solution) 0.248 mL in 247.5 mL of agar 
VORg (stock solution) 0.990 mL in 247.5 mL of agar 
aLonza BioWhittaker® (04-525F), bMillipore (R 1.08337.0250), cFrilabo (61101), dFisher-Scientific (BP904-100), eAcros 









The azole-containing SAB plates (nominal capacity of approximately 20 mL and 
100 mm) were prepared as follows: 
1. Azole stock solution was defrosted in advance at room temperature; 
2. 65g of SAB powder (VWR Chemicals BDH®, 84663.0500) (see Table 3.3.) were 
stirred until completely dissolved in 1 L of purified water and brought to boil with 
frequent stirring; 
3. The solution was distributed in 4 Erlenmeyer flasks (250 mL in each flask) and 
sterilized by autoclaving at 121ºC for 15 minutes; 
4. Agar was let to cool down until one was able to touch the flasks comfortably; 
5. The different azole stock solutions were added to each flask (see table 3.3.) and 
the remaining antifungal-free flask was used for the growth control plates, as 
follows: 
• Erlenmeyer 1: ITR (final concentration, 4 μg/mL) 
• Erlenmeyer 2: VOR (final concentration, 2 μg/mL) 
• Erlenmeyer 3: POS (final concentration, 0.5 μg/mL) 
• Erlenmeyer 4: growth control (antifungal-free plate); 
6. The agar from each flask was poured (approximately 20 mL per plate) to the 
respective sterile plates and let to solidify; 
7. The plates prepared were properly sealed and stored at 4ºC for up to 1 month 
from the date of preparation if there was no reduction in the height of agar. 
 
Table 3.3. Reagents to prepare 1 L of SAB (~50 agar-containing plates) 
Reagents and Formula Mass Weighted/Volume Pippeted 






Purified Water 1000 mL 
ITRb (stock solution) 2 mL in 250 mL of agar 
POSc (stock solution) 0.250 mL in 250 mL of agar 
VORd (stock solution) 1 mL in 250 mL of agar 




3.4.4. Preparation of the Inoculum Suspensions 
Prior to the preparation of the inoculum suspensions, A. fumigatus isolates were 
cultured on SAB medium and incubated at 25ºC to be able to sporulate. Inoculum 
suspensions were then prepared from fresh, mature (3- to 5-day-old), non-contaminated 
cultures, as follows: 
1. The conidia of up to five pure colonies of each isolate were carefully rubbed using 
a moist sterile cotton swab and subsequently suspended in 1000 μL of sterile 
water in a sterile Eppendorf and vortexed for 15 seconds with a vortex mixer at 
approximately 2000 rpm, ensuring homogeneity of the conidia suspension to 
avoid presence of clumps; 
2. 500 μL of sterile water plus 500 μL of the previous suspension were pipetted to 
a spectrophotometer (UNICAM Spectronic Helios β) cuvette, before measuring 
the absorbance at 600 nm in duplicate; 
3. The mean absorbance values of each suspension were calculated to a final 
optical density (OD) of 0.5 McFarland (OD600 = 0.060); 
4. At last, final inoculum suspensions were made with a calculated volume of the 
remaining fungal suspension, EGCG at final concentrations of 25 μg/mL, 50 
μg/mL, 100 μg/mL, 400 μg/mL and filled up to 1 mL with sterile water. For control 
purposes it was included an inoculum suspension without EGCG. Between 
experiments, the suspensions were kept frozen at -20ºC. 
 
EGCG dosage was selected considering that 400 mg and 800 mg of EGCG 
intake, which are considered safe doses previously used in human clinical trials result in 
peak serum concentrations in the range of 100 to 400 ng/mL (95). 
3.4.5. Inoculation and Incubation of Agar Plates 
25 μL of each final inoculum suspension were pipetted onto the previously 
prepared agar-containing plates without touching the surface, within 30 minutes of the 
preparation of the inoculum suspension to maintain viability of the conidia. In the first two 
experiments the fungal suspensions were inoculated in RPMI-1640 medium and in the 
last one they were suspended in SAB medium. Although the EUCAST protocol 
recommends an incubation time of 48h, the agar plates were incubated without agitation 
at 34-37ºC in ambient air for 7 days as the inoculum suspension had diluted amounts of 
fungi compared to the original protocol. 
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3.4.6. Reading and Interpretation of Results 
After incubation, the endpoint was read visually by recording the presence or 
absence of growth on each plate at 2, 4 and 7 days. Any growth on one or more azole-
containing agar plates was considered. The presence or absence of fungal growth on 
the surface of the four plates yielded the following preliminary classification: azole-
susceptible isolate: growth on the antifungal-free plate and absence of growth on the 
azole-containing plates at a given time; potentially an azole non-susceptible isolate: 
growth on the antifungal-free and on any of the azole-containing plates (11). 
The gathered data was then organized in tables using Microsoft® Excel (v. 16.36). 
3.5. Ethic 
The research project was previously approved by the course council in its own 
model, and then sent to the Lisbon School of Health Technology ethics board, obtaining 
a positive feedback (CE-ESTeSL-Nº. 24-2020). The authors certify that there was no 
actual or potential conflict of interest in relation to this research. As this was an in vitro 
study, without the need of animal models or biological samples from patients, no special 







4. Results and Discussion 
 
Tea is the most widely consumed beverage in the world and has been reported 
to have antimicrobial activities (10,96–98). Specifically, EGCG isolated from green tea 
has shown to have antifungal activity against a number of fungi (7,10). Thus, we aimed 
to find out if EGCG has in vitro antifungal potential against triazole-resistant Aspergillus 
fumigatus collected during exposure assessment campaigns, and if there are synergistic 
effects between EGCG and the clinically used triazoles.  
As mentioned earlier, the screening procedure was made in triplicate. In the first 
two experiments the fungal suspensions were inoculated in RPMI-1640 medium and in 
the last one they were suspended in SAB medium. Next, I analyze and discuss one by 
one, the results obtained from each experiment. 
4.1. A. fumigatus isolates have divergent growth patterns in azole-
containing plates (RPMI-1640 medium) in co-exposure with EGCG at 
different concentrations 
In Experiment I (see Table 4.1.) isolates 299 and 873 proved resistant to 2 μg/mL 
VOR and 4 μg/mL ITR since they grew in the presence of these drugs alone and with 
increasing concentrations of EGCG at all tested time points. Regarding POS-containing 
media both isolates initially (2d) showed no growth on 0.5 μg/mL POS but grew from 4d 
onward. This delay is possibly associated with the inherent dilution applied to the 
inoculum suspensions and goes according to the resistant phenotype of these isolates 
found in the Gonçalves et al (2021) (33) study. As such, the results presented so far 
point towards no effects of EGCG alone against these isolates nor synergism with any 
of the triazoles. 
Isolate 1209 grew in all media when EGCG was present without any triazole drug, 
showing no effects of increasing concentrations of this compound against this isolate. 
After 2 days it proved resistant to 2 μg/mL VOR in the presence of 2 μg/mL VOR alone 
and with 25 and 50 μg/mL of EGCG but showed no growth when the EGCG 
concentrations raised above 100 μg/mL. This is the most interesting finding, in a way 
that shows a potential sensitization when this isolate was exposed to 2 μg/mL VOR in 
addition to 100 μg/mL (or higher) of EGCG. This finding comes to suggest that EGCG, 
not only have synergistic antifungal potential against resistant C. albicans (6–
RESULTS 
 36 
8,12,79,85,99), but it might also have against triazole-resistant A. fumigatus. However, 
further studies should take place in order to prove strong relations between the use of 
EGCG and sensibilization of other-wise-resistant A. fumigatus isolates to triazoles. 
This antifungal synergism relation – the combination of antifungal agents that 
have enhanced antifungal activity when used together compared with the activity of each 
agent alone (12) – between EGCG and antifungal drugs have been previously reported 
in other fungi such as Candida spp.. For example, Navarro-Martínez et al (2006) (8) 
reported antifungal synergism between EGCG and inhibitors of the C. albicans 
ergosterol biosynthesis pathway (ITR and KET), lowering the MIC values of these 
agents, that ranged from 0,01-16 μg/mL (ITR) and 0,01-4 μg/mL (KET) alone, to 0,003- 
0,01 μg/mL (ITR) and 0,002-0,25 (KET) in combination with EGCG (8). Ning et al (2015) 
(99) also observed synergism between the catechin and miconazole (MCZ), FLC and 
AMB against both planktonic and biofilm cells of Candida species. MICs against Candida 
planktonic cells ranged from 375-1500 μg/mL (EGCG), 0,25-1 μg/mL (MCZ), 0,5-4 
μg/mL (FLC) and 0,063-0,25 μg/mL (AMB), while the lowest concentration of test agent 
which inhibited more than 80% metabolic activity of Candida biofilm cells (SMIC [sessile 
MIC]) showed obvious increases, ranging from 3000-24000 μg/mL (EGCG), 12,5-1600 
μg/mL (MCZ), 156,25-6400 μg/mL (FLC), and 0,63-6,25 μg/mL (AMB), clearly showing 
that all tested Candida biofilm cells were highly (20–3200 times) resistant to EGCG and 
antimycotics compared with their planktonic counterparts. When EGCG was in 
combination with MCZ or AMB, synergistic effects were observed against all tested 
Candida planktonic cells (MICs of MCZ reduced from 0,25-1 to 0,031-0,25 μg/mL; MICs 
of AMB reduced from 0,063-0,25 to 0,016-0,063 μg/mL) and against most Candida 
biofilms (SMICs of MCZ reduced from 12,5-3200 to 0,20-800 μg/mL; SMICs of AMB 
reduced from 0,63-6,25 to 0,13-1,56 μg/mL). For the EGCG plus FLC combination, 
however, no synergism was observed against both planktonic and biofilm cells of C. 
krusei and C. kefyr (99).  
However, none of that research showed synergism between EGCG and VOR 
specifically. As such, as far as I know this is the first report of an azole-resistant-A. 
fumigatus being potentially sensibilized to VOR in the presence of EGCG. This is 
particularly interesting, as the most common serious side effect, hepatotoxicity, occurs 
most often with VOR in up to 31% of the cases (12,35). 
It is noteworthy that this isolate presented growth after an incubation period of 7d 
which might be explained by the acquisition of VOR-resistance after prolonged 
incubation time. Actually, a study by Ricardo et al (2014) (100) reported such a 
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phenomena in a Candia species. They exposed a susceptible Candida krusei isolate 
daily to 1 μg/mL VOR, and after 5 days of exposure to VOR, they achieved a higher MIC 
value than the original, which remained constant after 25 additional days of treatment 
with VOR and also after 30 consecutive days of incubation in VOR-free medium (100). 
As to POS and ITR, isolate 1209 proved sensitive until day 7. The sensitive 
isolate didn’t grow in any of the media, proving its phenotype. 
 
Table 4.1. Experiment I: growth patterns of A. fumigatus isolates in different azole-containing 




W/o Antifungal 2 μg/mL VOR 0.5 μg/mL POS 4 μg/mL ITR 
















0 + + + + + + - + + + + + 
25 + + + + + + - + + + + + 
50 + + + + + + - + + + + + 
100 + + + + + + - + + + + + 
250 + + + + + + - + + + + + 
400 + + + + + + - + + + + + 
87
3 
0 + + + + + + - + + + + + 
25 + + + + + + - + + + + + 
50 + + + + + + - + + + + + 
100 + + + + + + - + + + + + 
250 + + + + + + - + + + + + 




0 + + + + + + - - - - - - 
25 + + + + + + - - - - - - 
50 + + + + + + - - - - - - 
100 + + + - - + - - - - - - 
250 + + + - - + - - - - - - 














0 + - - - - - - - - - - - 
25 - - - - - - - - - - - - 
50 - - - - - - - - - - - - 
100 - - - - - - - - - - - - 
250 - - - - - - - - - - - - 
400 - - - - - - - - - - - - 





The results from Experiment I triggers the will to know which phenomena is 
causing the sensibilization of the VOR-resistant isolate 1209. At this time, the reason for 
this is unknown. Further work is needed, and more isolates need to be tested to draw 
any conclusion from these observations. However, after some research, two plausible 
answers can be formulated. The VOR-resistant isolate 1209 may have been 
chemosensitized by EGCG at higher concentrations (≥ 100 μg/mL), leading to a 
vulnerability to VOR; or EGCG may play a role in epigenetic modulation on 1209 isolate 
phenotype, therefore contributing to the sensibilization to VOR when higher 
concentrations of EGCG are present. 
Chemosensitization involves enhancing the effectiveness of antifungal agents by 
co-applying a second compound. The second compound does not necessarily need to 
have much antifungal potency alone, but debilitates the ability of the fungus to launch a 
protective response to the antifungal agent (101). 
On the other hand, the fact that the three isolates presented differences in 
resistance patterns to VOR make us doubt the role genetics play in the resistance 
phenotype of A. fumigatus, as the cyp51A mutation found (TR34/L98H) was common in 
all of them. Could different epigenetic mechanisms among the isolates, despite having 
the same triazole-resistance mutation, be affecting their phenotype? Epigenetic 
mechanisms refer to cellular changes mediated by factors other than DNA sequence 
modifications that momentarily affect the expression of target genes, providing an 
additional route via which microorganisms can rapidly respond to changing environments 
and stresses, including drug stress (102). Generally, the epigenetic mechanisms are 
divided in two main categories: RNA-based and chromatin-based mechanisms. RNA-
based mechanisms include RNA interference (RNAi) and non-coding RNAs (ncRNAs). 
RNAi mechanism is mediated by small RNAs which selectively target complementary 
RNAs inducing degradation or inhibiting translation of target RNA and can also recruit 
heterochromatin proteins, inhibiting gene expression itself. ncRNAs are mainly long 
ncRNAs (> 200 bp), which comprise a high percentage of total RNA transcripts and also 
play a role in epigenetic gene regulation. Chromatin modifications can be chemical (post-
translational modifications [PTMs] of histone proteins and DNA methylation) or structural 
(chromatin remodeling and DNA-DNA interactions). The N-terminal tail of histones in 
nucleosomes act as substrates for several PTMs, including methylation, acetylation, and 
phosphorylation. Histone modifications are able to alter gene expression levels by 
allowing or restricting binding of transcription factors or enhancers. The enzymes 
responsible for mediating these modifications are called histone acetyltransferases 
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(HATs), whereas the ones responsible for removing these modifications are the histone 
deacetylases (HDACs). Acetylated histones lead to an open chromatin conformation 
(euchromatin) promoting transcription, whereas deacetylated histones inhibit 
transcription since the chromatin is compact (heterochromatin). DNA methylation is a 
process by which DNA methyltransferases (DNMTs) add methyl groups to the cytosine 
bases of DNA molecule, originating the 5-methylcytosine base modification (102). 
Hypomethylation promotes the activation of genes that are normally silenced, increasing 
the transcriptional activity, while hypermethylation promotes the opposite (103). At last, 
chromatin structure is dependent upon nucleosome positioning in the genome, a critical 
factor required for transcription initiation. It requires ATP-dependent nucleosome 
remodelers or looping of DNA sequences to alter between compact (nontranscribed) or 
loosen (transcribed) states (102). 
After thorough research, it was found that the epigenetic modulator potential of 
EGCG specifically on A. fumigatus, let alone triazole-resistant A. fumigatus have not 
been defined yet and in vitro experiments are currently lacking. However, EGCG’s 
epigenetic modulator potential have been proved on cancer physiopathology. Potenza 
et al (2020) (58) suggested that EGCG may carry out its health benefits not only due to 
its antioxidant nature, but also via receptor-mediated activation of multiple signaling 
pathways, and by acting as an epigenetic modulator of DNA methylation and chromatin 
remodeling, altering gene expression and modifying microRNA activities (58). Actually, 
several papers reported important anti-cancerous epigenetic properties of EGCG on 
certain types of human cancers, such as breast cancer (104), cervical cancer (105) or 
leukemia (106), among others. The DNA methylation mediated by specific DNMTs, is 
involved in the epigenetic silencing of multiple genes implicated in human breast 
carcinogenesis. Mirza et al (2013) (104) revealed that treatment with natural compounds, 
among which EGCG, resulted in a significant decrease in the transcript levels of all the 
DNMTs investigated, demonstrating that these compounds have the potential to reverse 
the epigenetic changes (104). In another study using human cervical cancer cell line 
HeLa, Khan et al (2015) (105) found that time-dependent EGCG-treated HeLa cells were 
found to have a significant reduction in the enzymatic activity of DNMT and HDAC, 
resulting in reactivation of known tumor-suppressor genes in HeLa cells due to marked 
changes in the methylation of the promoter regions of these genes (105). Borutinskaite 
et al (2017) (106) demonstrated EGCG might also be useful for acute promyelocytic 
leukemia (APL) treatment, due to its ability to inhibit APL cell proliferation and cause 
apoptosis through downregulation of epigenetic modifiers and hyperacetylation of 
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histones binding to the promoter regions of genes associated with cell cycle arrest and 
differentiation (106). 
 
The results obtained for isolates 299 and 873 in Experiment II (see Table 4.2.) 
are exactly the same as for these isolates in experiment I. Concerning isolate 1209 and 
the triazole-sensitive isolate, the results were somewhat different from those obtained in 
experiment I. Isolate 1209 showed no effects of EGCG alone at tested concentrations 
(resistant to all). It was also resistant to 2 μg/mL VOR, although it showed no growth in 
the absence of EGCG at 2d. As to POS it remained sensitive throughout the incubation 
period. While for 4 μg/mL ITR, it proved sensitive although it showed some growth from 
day 4 onward when the concentration of EGCG was 400 μg/mL, perhaps meaning some 
tolerance to prolonged exposure to these compounds. 
The triazole-sensitive isolate grew after 4 days in the media with no antifungal, 
confirming its phenotype. The fact that it didn’t grew in the presence of EGCG leads us 
to think EGCG exerted some kind of selective pressure in the azole-sensitive isolate. It 
interestingly demonstrates tolerance to 2 μg/mL VOR in the absence of EGCG after long 
exposure to it (7d incubation) and unsurprisingly did not grow in the POS and ITR-




















Table 4.2. Experiment II: growth patterns of A. fumigatus isolates in different azole-containing 




W/o Antifungal 2 μg/mL VOR 0.5 μg/mL POS 4 μg/mL ITR 
















0 + + + + + + - + + + + + 
25 + + + + + + - + + + + + 
50 + + + + + + - + + + + + 
100 + + + + + + - + + + + + 
250 + + + + + + - + + + + + 
400 + + + + + + - + + + + + 
87
3 
0 + + + + + + - + + + + + 
25 + + + + + + - + + + + + 
50 + + + + + + - + + + + + 
100 + + + + + + - + + + + + 
250 + + + + + + - + + + + + 




0 + + + - + + - - - - - - 
25 + + + + + + - - - - - - 
50 + + + + + + - - - - - - 
100 + + + + + + - - - - - - 
250 + + + + + + - - - - - - 














0 - + + - - + - - - - - - 
25 - - - - - - - - - - - - 
50 - - - - - - - - - - - - 
100 - - - - - - - - - - - - 
250 - - - - - - - - - - - - 
400 - - - - - - - - - - - - 






4.2. A. fumigatus isolates growth pattern in azole-containing plates (SAB 
medium) differ in co-exposure with EGCG at different concentrations when 
compared to RPMI-1640 medium 
At last, the results form Experiment III (see Table 4.3.) were substantially different 
from those obtained from Experiments I and II. Isolates 299 and 873 demonstrated 
growth on all triazole and non-triazole-containing media. 
Isolate 1209 showed no effect of exposure to EGCG, growing in all tested 
concentrations in media w/o triazoles. Initially, isolate 1209 didn’t grew on VOR-
containing media (except when in the presence of 400 μg/mL EGCG), but it proved 
resistant after 4d (for 0, 100 and 250 μg/mL EGCG) and only after 7d (for 25 and 50 
μg/mL EGCG). Apparently, isolate 1209 is resistant to 2 μg/mL VOR when EGCG is at 
a final concentration of 400 μg/mL. It was resistant to 0.5 μg/mL POS in absence of 
EGCG, stopped growing when in mutual presence of 0.5 μg/mL POS and EGCG at any 
tested concentration. It was sensitive to 4 μg/mL ITR (except when in the presence of 
400 μg/mL EGCG). At day seven it showed some kind of growth when the concentration 
of EGCG was either 0, 50 or 100 μg/mL, again suggesting tolerance after long incubation 
periods. 
The triazole-sensitive isolate grew in the absence of EGCG or antifungal and was 
sensitive to the presence of any concentration of EGCG or triazoles. 
Even though the growth of the triazole-resistant A. fumigatus isolates fits that 
from Gonçalves et al (2021) (33) (see Table 4.3.), attention should be given when 
analyzing the results from this experiment since the EUCAST screening procedure for 
the detection of azole resistance in Aspergillus fumigatus isolates indicates explicitly that 
fungal suspensions must be inoculated onto RPMI-1640 medium and not on the general-










Table 4.3. Experiment III: growth patterns of A. fumigatus isolates in different azole-containing 




W/o Antifungal 2 μg/mL VOR 0.5 μg/mL POS 4 μg/mL ITR 
















0 + + + + + + + + + + + + 
25 + + + + + + + + + + + + 
50 + + + + + + + + + + + + 
100 + + + + + + + + + + + + 
250 + + + + + + + + + + + + 
400 + + + + + + + + + + + + 
87
3 
0 + + + + + + + + + + + + 
25 + + + + + + + + + + + + 
50 + + + + + + + + + + + + 
100 + + + + + + + + + + + + 
250 + + + + + + + + + + + + 




0 + + + - - + + + + - - + 
25 + + + - + + - - - - - - 
50 + + + - + + - - - - - + 
100 + + + - - + - - - - - + 
250 + + + - - + - - - - - - 














0 + + + - - - - - - - - - 
25 - - - - + - - - - - - - 
50 - - - - - - - - - - - - 
100 - - - - - - - - - - - - 
250 - - - - - - - - - - - - 
400 - - - - - - - - - - - - 











In the course of this study, we encounter some limiting factors. The major and 
most obvious one is the fact that laboratory-based in vitro experiments can’t always 
accurately simulate real-life situations and don’t necessarily translate to biological animal 
and human models, even though they are effective for testing causal relationships 
between variables and proving concepts. Another major limitation was the lack of 
knowledge and scientific evidence specifically about this topic, as there is some research 
directed to EGCG activity against several microorganisms, including fungi, but very little 
about the effects of triazoles and EGCG together against triazole-resistant A. fumigatus. 
The reduced number of isolates also posed a limitation, since it prevented us from 
applying statistical inference, thus reducing the certainty of the results presented. At last, 
other limiting factor common to studies of this kind was the limited budget. I couldn’t 
forget to mention all the physical, psychological and logistic barriers imposed to master 
students who managed to finish their dissertations while fighting the SARS-CoV-2 
pandemic. 
4.4. Future Work 
In order to overcome these limitations, I highly recommend further experiments 
be carried out with a more heterogeneous (perhaps including healthcare isolates) and 
greater sample size so the results are even more reliable and statistic conclusions can 
be drawn. Considering the previously described and established epigenetic modulator 
potential of EGCG against cancer (84,104–106), it would be extremely relevant to 
understand if there is any epigenetic mechanism leading to the different drug responses 
observed in the isolates, since all had the same triazole-resistant mutation. In a broader 
sense, it would be interesting to evaluate the epigenetic potential of these compound 
against fungi aiming the development of novel epigenetic-based antifungal therapy. As 
stated before, EGCG has in general a low bioavailability (87–89) hence, the translation 
of its antifungal synergistic in vitro effects into clinically relevant strategies is also a 






Invasive fungal infections caused by triazole-resistant fungi, including Aspergillus 
fumigatus, are becoming an important cause of human disease with associated high 
morbidity and mortality rates worldwide. Increasing resistance to the limited arsenal of 
antifungal drugs is a serious public health concern. As such, the development of new 
approaches and strategies to tackle the growing antifungal resistance crisis have 
become essential. This includes the assessment of new compounds with known 
antimicrobial properties, to be utilized as novel agents or adjuvants in antifungal 
pharmacologic therapy. In this regard, researchers mainly focused on the antifungal 
effects of EGCG against yeasts such as Candida spp. and molds such as 
dermatophytes, lacking scientific evidence towards A. fumigatus. In a way, this work 
came to fill this literature void. I tested and then discussed the in vitro antifungal effects 
of EGCG against triazole-resistant Aspergillus fumigatus isolates collected during 
exposure assessment campaigns performed in the last ten years in Portugal and abroad 
in different work environments, and its potential synergistic effects with clinically used 
triazoles, namely ITR, VOR and POS. 
In fact, EGCG alone showed no effects on triazole-resistant A. fumigatus isolates, 
as it didn’t have the ability to reverse the resistance phenotype of these strains. 
Regarding isolate 1209, it proved resistant to VOR in the presence of 2,0 μg/mL of VOR 
alone and with 25 and 50 μg/mL of EGCG but it showed no growth when the EGCG 
concentrations raised above 100 μg/mL, potentially showing it somehow sensitized the 
isolate to 2 μg/mL VOR.  In summary, we demonstrated the potential synergistic effects 
of EGCG with 2 μg/mL VOR against triazole-resistant A. fumigatus. It comes as a way 
to lower the dosages of triazoles, thus preventing adverse effects and the emergence of 
triazole-resistant A. fumigatus, and to enhance the antifungal effects by achieving a 
synergistic killing effect. 
There is still a long way to go, and future work is needed before EGCG can be 
routinely administered as an antifungal drug in immunocompromised patients. In the 
actual panorama however, we hope these exciting findings stimulate further research on 
EGCG and provide a scientific foundation that ultimately may translate into the use of 
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